WallStSmart

AptarGroup Inc (ATR)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 43% more annual revenue ($5.40B vs $3.78B). RMD leads profitability with a 27.5% profit margin vs 10.4%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

ATR

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 4.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.57

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRSignificantly Overvalued (-250.2%)

Margin of Safety

-250.2%

Fair Value

$39.98

Current Price

$125.82

$85.84 premium

UndervaluedFair: $39.98Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATR0 strengths · Avg: 0/10

No standout strengths identified

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

ATR3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.062/10

Expensive relative to growth rate

EPS GrowthGrowth
-23.5%2/10

Earnings declined 23.5%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ATR

Revenue growth of 13.5% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : ATR

The primary concerns for ATR are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

ATR profiles as a value stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

ATR is growing revenue faster at 13.5% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 53/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AptarGroup Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AptarGroup, Inc. offers a range of packaging, dispensing and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectables, and food and beverage markets. The company is headquartered in Crystal Lake, Illinois.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?